Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.

被引：0
|
作者：
Vassilev, Zdravko
Fan, Xiaozhou
Ostojic, Helene
Xu, Julie
Barzi, Afsaneh
机构：
[1] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[2] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [41] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Final survival and pharmacogenomic profiling results from the OPAL study
    Bokemeyer, C.
    Atanackovic, D.
    Stoehlmacher, J.
    Hildebrandt, B.
    Stuebs, P.
    Steffens, C.
    Brugger, W.
    Hapke, G.
    Illerhaus, G.
    Bluemner, E.
    Stein, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 100 - 100
  • [42] FOLFOXIRI therapy with bevacizumab in metastatic colorectal cancer patient: Systematic review
    Subroto, Dion Ravinder Theodeus
    Sutanto, Mario
    Law, Natasha Karlina
    Lee, Jonathan Vincent
    Kumar, Chandni
    Siregar, Axel Sebastian
    Sihombing, Andreas
    Ang, Xavier Manuel
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2023, 34 : S1459 - S1459
  • [43] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
    Antoniotti, Carlotta
    Rossini, Daniele
    Pietrantonio, Filippo
    Salvatore, Lisa
    Marmorino, Federica
    Ambrosini, Margherita
    Lonardi, Sara
    Bensi, Maria
    Moretto, Roberto
    Tamberi, Stefano
    Toma, Ilaria
    Passardi, Alessandro
    De Grandis, Maria Caterina
    Conca, Veronica
    Palermo, Federica
    Cappetta, Alessandro
    Catteau, Aurelie
    Boni, Luca
    Galon, Jerome
    Cremolini, Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] A phase II study of cadonilimab plus FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
    Lin, R.
    Zhao, S.
    Su, L.
    Hong, Y.
    Luo, J.
    Wei, Y.
    Zhao, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1519 - S1519
  • [46] Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
    Sunakawa, Y.
    Usher, J.
    Satake, H.
    Jaimes, Y.
    Miyamoto, Y.
    Nakamura, M.
    Kataoka, M.
    Shiozawa, M.
    Takagane, A.
    Terazawa, T.
    Watanabe, T.
    Ishigure, K.
    Tanaka, C.
    Sekikawa, T.
    Takeuchi, M.
    Fujii, M.
    Danenberg, K.
    Danenberg, P. V.
    Lenz, H-J.
    Ichikawa, W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Phase II trial of bevacizumab (B) plus everolimus (E) for refractory metastatic colorectal cancer (mCRC).
    Altomare, I.
    Russell, K. B.
    Uronis, H. E.
    Morse, M.
    Hsu, S. D.
    Zafar, Y.
    Bendell, J. C.
    Starodub, A.
    Honeycutt, W.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials
    Cremolini, C.
    Loupakis, F.
    Masi, G.
    Lonardi, S.
    Granetto, C.
    Mancini, M. L.
    Chiara, S.
    Moretto, R.
    Rossini, D.
    Vitello, S.
    Allegrini, G.
    Tonini, G.
    Bergamo, F.
    Tomasello, G.
    Ronzoni, M.
    Buonadonna, A.
    Bustreo, S.
    Barbara, C.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27 (05) : 843 - 849
  • [50] Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)
    Sunakawa, Y.
    Shiozawa, M.
    Kawai, T.
    Ota, H.
    Yasui, H.
    Kochi, M.
    Manaka, D.
    Ohori, H.
    Matsuura, M.
    Shinohara, Y.
    Takeuchi, M.
    Ichikawa, W.
    Fujii, M.
    Tsuji, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S20 - S20
12345